Evidence map›Paper›PMID 25693189›Full record

ArticlePloS one2015

Antagonistic antiviral activity between IFN-lambda and IFN-alpha against lethal Crimean-Congo hemorrhagic fever virus in vitro.

Licia Bordi, Eleonora Lalle, Claudia Caglioti, Damiano Travaglini, Daniele Lapa, Patrizia Marsella, Serena Quartu, Zoltan Kis, Kevin K Arien, Hartwig P Huemer and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Viral replicon particles protect IFNARAntiviral research · 2021
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 4 countries.

Licia BordiLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Eleonora LalleLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Claudia CagliotiLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Damiano TravagliniLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Daniele LapaLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Patrizia MarsellaLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Serena QuartuLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Zoltan KisDivision of Virology, National Center for Epidemiology, Budapest, Hungary.
Kevin K ArienUnit of Virology, Institute of Tropical Medicine, Antwerp, Belgium.
Hartwig P HuemerDepartment of Hygiene, Microbiology & Social Medicine, Medical University Innsbruck, Innsbruck, Austria.
Silvia MeschiLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Giuseppe IppolitoScientific Direction, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Antonino Di CaroLaboratory of Microbiology and Biorepository, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Maria R CapobianchiLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Concetta CastillettiLaboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITInnsbruck Medical University · ATInstituut voor Tropische Geneeskunde · BENational Center for Epidemiology · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsCrimean Congo Hemorrhagic fever virus (CCHFV) is the causative agent of Crimean-Congo hemorrhagic fever, a severe disease with a mortality rate of around 30% in humans. Previous studies demonstrate that pre-treatment with type I IFNs have an antiviral effect against CCHFV, while established CCHFV infection is almost insensitive to subsequent IFN-α treatment. No data concerning type III IFNs antiviral activity against CCHFV are available so far. The aim of the present study was to explore the capability of IFN-λ1 to inhibit the replication of CCHFV and the possible synergism/antagonism between IFN-α and IFN-λ1 both in the inhibition of CCHFV replication and in the activation of intracellular pathways of IFN response.

methodsHuman A549 and HuH7 cells were treated with increasing amounts of IFN-λ1, or IFN-α or a combination of them, infected with CCHF; the extent of virus yield inhibition and the induction of MxA and 2'-5'OAS mRNA was measured. RESULTS AND

conclusionsOur study pointed out that type III IFN possess an antiviral activity against CCHFV, even if lower than type I IFN. Moreover, a clear antagonism between IFN-λ and IFN-α was observed in both cell lines (A549 and HuH7 cells), in terms of antiviral effect and activation of pivotal ISGs, i.e. MxA and 2'-5'OAS. Elucidating the interplay between type I and III IFNs will help to better understand innate defence mechanisms against viral infections and may provide novel scientific evidence for a more rational planning of available and future treatments, particularly against human diseases caused by high concern viruses.

Indexed as

AnimalsAntiviral AgentsCell LineDose-Response Relationship, DrugDrug AntagonismHemorrhagic Fever Virus, Crimean-CongoHumansInterferon-alphaInterferon LambdaInterferonsInterleukinsIntracellular SpaceVirus ReplicationAntiviral AgentsInterferon-alphaInterferon Lambdainterferon-lambda, humanInterferonsInterleukins

Identifiers

PMID25693189
PMCPMC4333211
OpenAlexW2081515125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.